Effectiveness and Safety of Oral Propranolol versus Other Treatments for Infantile Hemangiomas: A Meta-Analysis.
Effectiveness and Safety of Oral Propranolol versus Other Treatments for Infantile Hemangiomas: A Meta-Analysis.
复制标题
口服普萘洛尔与其他治疗婴儿血管瘤的有效性和安全性：荟萃分析
DOI：
10.1371/journal.pone.0138100
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Zhang L
中科院分区：
文献类型：
--
作者：
Liu X;Qu X;Zheng J;Zhang L
评价婴儿血管瘤治疗的流行病学研究产生了不一致的结果。对已发表的数据进行荟萃分析，以研究口服普萘洛尔与其他治疗婴儿血管瘤的有效性和安全性。基于PubMed、EMBASE和奥维德搜索引擎上的文献（1960年至2014年12月1日发表）进行荟萃分析。估计结局指标的合并比值比（OR）和95%置信区间（CI）。进行了异质性、发表偏倚和亚组分析。共有61项研究（涉及5，130名受试者）符合纳入标准。普萘洛尔被认为是一个更有效的方式在治疗IH（OR = 0.92; 95%CI，0.89-0.95），与包括全身性类固醇在内的其他治疗相比，并发症较少（OR = 0.68; 95% CI，0.59-0.76）;激光消融（OR = 0.55; 95%CI，0.43-0.67）;其他β-肾上腺素能受体阻滞剂（OR = 0.56; 95%CI，0.50-0.61）和手术（OR = 0.55; 95%CI，0.28-0.81）。普萘洛尔的亚组分析显示，2 mg/kg/天或更高剂量产生更好的结局（OR = 0.92; 95% CI，0.88-0.95; OR = 0.95; 95% CI，0.89-1.00），既往未接受过普萘洛尔治疗的IH对普萘洛尔治疗的反应更好（OR = 0.95; 95% CI，0.91-0.98）。Meta分析显示普萘洛尔治疗IH的疗效优于其他药物。它提供了强有力的证据支持普萘洛尔作为IH的一线治疗。
Epidemiological studies evaluating treatments for infantile hemangiomas have produced inconsistent results. A meta-analysis of published data was conducted to investigate the effectiveness and safety of oral propranolol versus other treatments for infantile hemangiomas. A meta-analysis was conducted based on literature (published from 1960 to December 1, 2014) found on the PubMed, EMBASE, and OVID search engines. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were estimated for the outcome measures. Heterogeneity, publication bias and subgroup analysis were performed. A total of 61 studies involving 5,130 participants met the inclusion criteria. Propranolol was found to be a more effective modality in treating IHs (ORs = 0.92; 95%CI, 0.89–0.95) and had fewer complications compared to the other treatments including systemic steroids (ORs = 0.68; 95% CI, 0.59–0.76); laser ablation (ORs = 0.55; 95% CI, 0.43–0.67); other beta-adrenergic blockers (ORs = 0.56; 95% CI, 0.50–0.61) and surgery (ORs = 0.55; 95% CI, 0.28–0.81). A subgroup analysis of propranolol showed that a dose of 2 mg/kg/day or more yielded better outcomes (ORs = 0.92; 95% CI, 0.88–0.95; ORs = 0.95; 95% CI, 0.89–1.00), and IHs that had not been previously treated had better responses to propranolol treatment (ORs = 0.95; 95% CI, 0.91–0.98). The meta-analysis demonstrated that propranolol was more effective and safer than other therapies in treating IHs. It provides strong evidence for supporting the use of propranolol as a first-line therapy for IHs.
DOI：
10.5114/wo.2012.31774
发表时间：
2012
期刊：
Contemporary oncology (Poznan, Poland)
影响因子：
--
作者：
Meng J;Li Z;Gu Q;Zhang J;Zhuang Q;Si Y;Zhang A
通讯作者：
Zhang A
影响因子：
1.5
作者：
Hassan BA;Shreef KS
通讯作者：
Shreef KS